Efficacy and safety of recombinant human endostatin combined with whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer
- 3 July 2022
- journal article
- research article
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 174, 44-51
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Recombinant human endostatin combined with radiotherapy in the treatment of brain metastases of non-small cell lung cancerClinical and Translational Oncology, 2013
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapyProceedings of the National Academy of Sciences, 2012
- Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guidelinePractical Radiation Oncology, 2012
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trialThe Lancet Oncology, 2009
- Whole brain radiotherapy with radiosensitizer for brain metastasesJournal of Experimental & Clinical Cancer Research, 2009
- Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cellsBiochemical and Biophysical Research Communications, 2007
- Angiogenesis in brain tumoursNature Reviews Neuroscience, 2007
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- The relationship between temporal variation of hypoxia, polarographic measurements and predictions of tumour response to radiationPhysics in Medicine & Biology, 2004